![](/img/cover-not-exists.png)
The validity of biomarkers as surrogate endpoints in Alzheimer’s disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES)
C. C. Gispen-De Wied, M. Kritsidima, A. J. A. ElferinkVolume:
13
Language:
english
Pages:
12
DOI:
10.1007/s12603-009-0049-2
Date:
April, 2009
File:
PDF, 107 KB
english, 2009